Goldman Sachs Aktienanleihe BAYN .../ DE000GG2Q4Z7 /
5/13/2024 10:51:30 AM | Chg.0.00 | Bid1:57:29 PM | Ask1:57:29 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
100.15EUR | 0.00% | 100.15 Bid Size: 1 mill. |
100.22 Ask Size: 1 mill. |
BAYER AG NA O.N. | 20.00 - | 6/26/2024 | Call |
GlobeNewswire
1:30 PM
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transt...
GlobeNewswire
7:00 AM
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/2
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
4/18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
4/16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
4/11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
3/25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
3/6
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
3/4
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
2/13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire
2/13
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
GlobeNewswire
1/5
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
GlobeNewswire
1/4
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary end...
GlobeNewswire
12/14/2023
Iktos and Bayer Announce Collaboration to expand the use of Artificial Intelligence to Design New Su...